Efficacy observation of pomalidomide-based regimen in treatment of relapsed/refractory multiple myeloma
10.3760/cma.j.cn115356-20210923-00228
- VernacularTitle:泊马度胺为基础方案治疗复发难治多发性骨髓瘤效果观察
- Author:
Youfan FENG
1
;
Xiaofang WEI
;
Xinlian ZHANG
;
Qike ZHANG
;
Li ZHAO
;
Yuan FU
;
Yangyang ZHAO
;
Xiujuan HUANG
;
Qingfen LI
Author Information
1. 甘肃省人民医院血液科，兰州 730000
- Keywords:
Multiple myeloma;
Recurrence;
Refractory;
Pomalidomide;
Drug therapy, combination
- From:
Journal of Leukemia & Lymphoma
2022;31(4):218-222
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the early efficacy and safety of pomalidomide-based regimen in relapsed/refractory multiple myeloma (MM) in the real world.Methods:The clinical data of 15 patients with relapsed/refractory MM treated with pomalidomide-based regimen who were admitted to Gansu Provincial Hospital from January 2021 to July 2021 were retrospectively analyzed, and the early efficacy and safety were also evaluated.Results:There were 8 males and 7 females, and the median age of onset of 15 patients was 60 years (43-83 years); the median time for the diagnosis of relapse and refractory was 15 months (4-84 months). All 15 patients previously received bortezomib-based treatment regimens, 9 patients previously received lenalidomide treatment, and 7 cases received autologous hematopoietic stem cell transplantation. All patients received pomalidomide-based regimen combined with two-drug or three-drug regimen (pomalidomide combined with bortezomib,daratumumab,bendamustine, dexamethasone, cyclophosphamide or lenalidomide). The median treatment cycle was 2 cycles (2-4 cycles). After 2 cycles of treatment, the therapeutic efficacy was evaluated; the overall response rate was 73% (11/15), including 3 cases of complete remission, 3 cases of very good partial remission, and 5 cases of partial remission. Hematological toxicity occurred in 9 patients, of which 5 cases had grade 3-4 hematological toxicity, 4 cases had grade 1-2 hematological toxicity, and other adverse reactions were mild and tolerable.Conclusion:Pomalidomide-based regimen is effective and safe for relapsed/refractory MM patients.
